PMID: 9428493Jan 15, 1998Paper

The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol

Cancer
R SilvestriniG Bolis

Abstract

The aim of this study was to define the clinical relevance of functional biomarkers, prospectively assessed in a randomized clinical protocol, in patients with Stage III-IV epithelial ovarian cancer. The protocol compared cisplatin with polychemotherapy that included cisplatin and cyclophosphamide. In a subset of 168 patients with invasive epithelial ovarian cancer cell proliferation was determined by the 3H-thymidine labeling index, DNA ploidy was assessed by flow cytometry, and the expression of p53, bcl-2, and glutathione S-transferase-pi (GST-pi) was evaluated by immunohistochemistry using the antibodies PAb1801, anti-bcl-2, and GST-pi, respectively. Cell proliferation, DNA ploidy, and the expression of p53, bcl-2, and GST-pi were generally unrelated to one another and unrelated to clinicopathologic features, except for an association between DNA ploidy and the rate of cell proliferation. All biologic variables except bcl-2 were slightly related to tumor grade. DNA ploidy emerged as a predictor of clinical complete response and 3-year overall survival, regardless of treatment type or residual disease. Conversely, except for a favorable outcome for patients with tumors not expressing bcl-2 who were treated with cisplatin, no...Continue Reading

References

Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R SilvestriniG Bolis
Jun 1, 1990·American Journal of Obstetrics and Gynecology·V M BarnabeiJ R Lurain
Oct 1, 1989·Gynecologic Oncology·R SilvestriniR Colombi
Jan 15, 1987·Cancer·C J RodenburgG J Fleuren
Nov 1, 1994·Cancer·J PfistererA Pfleiderer
Apr 1, 1994·Gynecologic Oncology·W H GajewskiD A Bell
Jan 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J S BerekG J Rustin
Dec 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A Di LeoS Oriana
Jul 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M G DaidoneR Silvestrini

❮ Previous
Next ❯

Citations

Sep 13, 2005·Gynecologic Oncology·Giovanni D AlettiWilliam A Cliby
Jul 7, 2000·Seminars in Surgical Oncology·C H Holschneider, J S Berek
Jan 6, 2006·Obstetrics and Gynecology·Giovanni D AlettiWilliam A Cliby
Jul 2, 2003·Nature Reviews. Cancer·Roshan Agarwal, Stan B Kaye
Apr 19, 2013·Journal of Cancer Research and Clinical Oncology·Linjuan XuZehua Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.